MedPharm: Increased investment driving developments in topical drugs market
We caught up with MedPharm at CPHI North America to discuss opportunities in the topical and transdermal products space.
The topical drugs market is set to grow by $70.95 billion between 2021 and 2026, according to a recent market report from Technavio. This growth is attributed to an increase in the prevalence of skin diseases and is leading to heightened demand for the services of developers and manufacturers in the space.
According to Lynn Allen, Vice President of Business Development at MedPharm, the topical drugs market has also benefited from increasing investment in recent years. MedPharm is a global Contract Development and Manufacturing Organisation (CDMO) that provides topical and transdermal product design, development, and manufacturing services.
To keep up with increasing demand, the company has been expanding its North Carolina facility, where it conducts performance testing, and completed a £1.5 million refurbishment and expansion of its campus in Surrey, UK this year, increasing UK laboratory space by 35%.
‘In 2021 we saw a lot of investment in the space. We deliver things topically which includes the skin but also includes inhalation - so nasal and lung - ophthalmic, otic, transungual, and transmucosal. We saw a lot of interesting investment in assets targeting disease indications for those delivery routes,’ Allen said.
‘So, we’ve seen a lot of demand for our services and as we talk to other people within the industry, we see it's not just us - we're seeing a lot of that across the market.’
The Technavio report also notes the fragmented nature of the topical drugs market, due to the presence of large, established players such as Bayer AG and GlaxoSmithKline and smaller players like Crescita Therapeutics and Easton Pharmaceuticals.
According to Allen, MedPharm’s ‘robust development process’ and emphasis on de-risking differentiates the company from its market rivals.
‘We're not the kind of company that works to just shove an API into a base formulation,’ she said.
‘What we want to do is really a de-risk programmes by doing the work up front in order to make sure we’re de-risking the process – so, choosing the right compound, choosing the right formulations, choosing the right process in order to manufacture.’
Allen believes this approach, which utilises the company’s performance testing models, allows MedPharm’s clients to ‘fail fast’ and avoid ineffective clinical trials, which can have significant financial implications.
The company hopes to build connections with current and potential clients as an exhibitor at CPHI North America this year.
Allen said: ‘We appreciate CPHI's relationship with the industry, both the European event as well as the North American event. It has always been a really good chance for us to not only connect with current companies that we're dealing with, but also see new companies.
And the fact that it is held in Philadelphia - we find that to be a very nice opportunity for us to see a lot of our East Coast-based clients.’
MedPharm is located at stand 622 on the show floor.
Related News
-
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News Roche breaks into the obesity drug market with the acquisition of Carmot Therapeutics
In a bid to diversify their therapeutic offerings, Roche takes over Carmot Therapeutics in $2.7 billion deal, with one obesity drug spearheading the venture into the field as they prep for a Phase II in-human trial. -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News Women in Pharma: Delivering solutions for gender diversity
In our new monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona Speaker Interview – What the US FDA’s Quality Management Maturity Means for the Pharma Industry
At CPHI Barcelona (24–26 October, 2023), we spoke to Sireesha Yadlapalli, CEO of Pharmatech Associates, who gave a presentation on the implications of the US FDA’s Quality Management Maturity (QMM) Initiative, and spoke on the panel of the ... -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Wegovy and weight-loss drugs driving demand for manufacturers that can fill syringes
Injectable weight-loss treatments are prompting contract manufacturers to invest and include fill-finish services into their service portfolios, in a bid to attract pharmaceutical giants developing drugs similar to Novo Nordisk's Wegovy.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance